Search

Vasomera

Budiodarone

Budiodarone (ATI-2042) is an antiarrhythmic related to amiodarone that is currently being studied in clinical trials.

Etifoxine

Etifoxine is an anxiolytic and anticonvulsant drug developed by Hoechst in the 1960s. It is used in anxiety disorders and to promote peripheral nerve healing. … It does not bind to the benzodiazepine receptor though the effects are similar to that of benzodiazepines. It is more effective than lorazepam as an anxiolytic, and has fewer side effects.

Verubecestat

In the study, administration of Verubecestat at doses of 12, 40 and 60 mg resulted in a dose-dependent and sustained reduction in the levels of Ab40, a measure of BACE1 activity, in CSF from baseline of … In July 2013, Merck announced positive results for Phase Ib trials of Verubecestat.

EGS21

GC is a glycolipid that has been shown by Enzo scientists and collaborators to act as an anti-inflammatory agent in animal model systems, and therefore is being evaluated as an important candidate … drug in the treatment of various immune mediated diseases, such as Crohn's disease, hepatitis, non-alcoholic steatohepatitis (NASH) or fatty liver and HIV.

VLTS-934

It was under investigation in clinical trial NCT00113009 (Trial of VLTS-934 in Subjects With Intermittent Claudication Secondary to Peripheral Arterial Disease). … VLTS-934 was developed by Valentis inc. for the treatment of Peripheral Arterial Disease (PAD).

Darapladib

Desmoteplase

Desmoteplase is a chemical in the saliva of vampire bats. It activates plasminogen to the serine protease, plasmin. Plasmin acts by breaking down fibrin blood clots. … When a vampire bat bites its victim, it secretes an enzyme that prevents the blood from clotting.

R411

R411 is a non-steroid oral medicine for the treatment of asthma. It is not immunosuppressive, but blocks the activation and recruitment of cells involved in respiratory inflammation. … It is a dual-acting competitive integrin antagonist (as compared to previously developed single integrin antagonists or SIAs) that prevents binding of V-CAM1 to either a4b1 or a4b7.

LX1031

LX1031 is designed to act locally in the gastrointestinal tract by reducing the serotonin available for receptor activation, without affecting serotonin levels in the brain or its central nervous system … LX1031 is an orally-dosed drug candidate for irritable bowel syndrome and other gastrointestinal disorders.